---
title: "Foundayo (orforglipron) in chronic weight management: Safety questions"
description: "Safety questions on Foundayo (orforglipron) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects and Warnings. Questions: What are the most common side effects of Foundayo? What are the long-term side effects of Foundayo in trials up to 72 weeks? How common are nausea and stomach side effects with Foundayo? Does Foundayo nausea go away over time? 20 further questions follow. 24 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Foundayo (orforglipron) in chronic weight management: Safety questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Foundayo](https://uspl.lilly.com/foundayo/foundayo.html#pi)

## Side effects

<a id="foundayo-side-effects"></a>

### What are the most common side effects of Foundayo?

> “Most common adverse reactions, reported in ≥5% of patients treated with FOUNDAYO, are nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and hair loss. (6.1)”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Most%20common%20adverse%20reactions%2C%20reported,flatulence%2C%20and%20hair%20loss.%20%286.1%29)

> “The most common adverse reactions occurring more frequently with Foundayo than with placebo were primarily GI related.<sup>1</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=The%20most%20common%20adverse%20reactions,with%20placebo%20were%20primarily%20GI)

<a id="foundayo-long-term-side-effects"></a>

### What are the long-term side effects of Foundayo in trials up to 72 weeks?

> “Pool of Two Placebo-Controlled Clinical Trials: FOUNDAYO was evaluated for safety in a pool of two randomized, double-blind, placebo-controlled trials that included 3155 adult patients with obesity or overweight treated with FOUNDAYO once daily for up to 72 weeks and a 2-week off-drug follow-up period (Trial 1 and Trial 2) [see Clinical Studies (14)]. The mean age of patients was 49 years and 41% were male. The population was 60% White, 25% Asian, 8% Black or African American, and 0.3% American Indian or Alaska Native; 35% identified as Hispanic or Latino ethnicity. At baseline, patients had an average BMI of 36.5 kg/m2, 51% with a BMI ≥35 kg/m2, 50% with hypertension, 49% with dyslipidemia, 31% with type 2 diabetes, 11% with obstructive sleep apnea, 3% with coronary artery disease, and 3% with cerebrovascular disease.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Pool%20of%20Two%20Placebo%2DControlled%20Clinical,and%203%25%20with%20cerebrovascular%20disease.)

> “Table 1: Adverse Reactions Reported in ≥5% of FOUNDAYO-treated Adult Patients with Obesity or Overweight (With or Without Type 2 Diabetes) in Pool of Placebo-Controlled Trials (Trials 1 and 2)
>
> a Includes other related terms.
>
>
> Adverse Reaction	Placebo
> (N=1,576)
> %	FOUNDAYO
> 5.5 mg once daily
> (N=1,051)
> %	FOUNDAYO
> 9 mg once daily
> (N=1,055)
> %	FOUNDAYO
> 17.2 mg once daily
> (N=1,049)
> %
> Nausea	10	26	34	35
> Constipation	9	20	27	24
> Diarrhea	11	21	23	25
> Vomiting	4	13	21	24
> Dyspepsia	4	12	16	13
> Abdominal paina	7	13	14	14
> Headache	7	8	9	9
> Abdominal distension	3	7	9	8
> Fatiguea	4	6	7	9
> Eructation	1	6	8	8
> Gastroesophageal reflux disease	2	6	6	7
> Flatulence	2	5	6	6
> Hair lossa	2	4	4	5”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Table%201%3A%20Adverse%20Reactions%20Reported,5)

Note: Columns are placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg once daily, in that order (% of patients). The trials used an investigational orforglipron formulation at dosages equivalent to once-daily Foundayo.

<a id="foundayo-gi-side-effects"></a>

### How common are nausea and stomach side effects with Foundayo?

> “In a pool of Trials 1 and 2, gastrointestinal adverse reactions occurred more frequently among patients treated with once daily FOUNDAYO 5.5 mg (60%), 9 mg (68%), and 17.2 mg (69%) than placebo (37%). More patients treated with once daily FOUNDAYO 5.5 mg (3%), 9 mg (6%), and 17.2 mg (6%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.7%).
>
> Of the FOUNDAYO-treated patients who reported GI adverse reactions, 60%, 36%, and 4% reported mild or moderate or severe adverse reactions, respectively. The incidence of nausea, vomiting, and diarrhea was higher during the FOUNDAYO dosage escalation period and decreased over time.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20a%20pool%20of%20Trials,period%20and%20decreased%20over%20time.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-nausea-duration"></a>

### Does Foundayo nausea go away over time?

> “The incidence of nausea, vomiting, and diarrhea was higher during the FOUNDAYO dosage escalation period and decreased over time.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=The%20incidence%20of%20nausea%2C%20vomiting%2C,period%20and%20decreased%20over%20time.)

<a id="foundayo-discontinuation"></a>

### How many patients stopped Foundayo because of side effects?

> “Across both trials, 8% of patients treated with FOUNDAYO (5.5 mg, 6%; 9 mg, 9%; and 17.2 mg, 10%) once daily permanently discontinued treatment as a result of adverse reactions compared to 3% of patients receiving placebo. The majority of patients (5%) who discontinued FOUNDAYO due to adverse reactions did so due to gastrointestinal adverse reactions.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Across%20both%20trials%2C%208%25%20of,due%20to%20gastrointestinal%20adverse%20reactions.)

> “Table of discontinuation rates due to adverse reactions comparing Foundayo vs placebo in the ATTAIN-1 and ATTAIN-2 trials. There were 1051, 1055, 1049, and 1576 total adults for Foundayo 5.5 mg, 9 mg, 17.2 mg, and placebo, respectively. Discontinuation rates due to adverse reactions were 6% for Foundayo 5.5 mg, 9% for Foundayo 9 mg, 10% for Foundayo 17.2 mg, and 3% for placebo. Discontinuation rates due to gastrointestinal adverse reactions were 3% for Foundayo 5.5 mg, 6% for Foundayo 9 mg, 6% for Foundayo 17.2 mg, and 0.7% for placebo.”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=Table%20of%20discontinuation%20rates%20due,mg%2C%20and%200.7%25%20for%20placebo.)

On the page, select: Table description

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-heart-rate"></a>

### Does Foundayo increase heart rate?

> “In a pool of Trials 1 and 2, tachycardia (tachycardia, heart rate increased, and sinus tachycardia) was reported in 3% of patients treated with FOUNDAYO and 0.9% receiving placebo. Treatment with FOUNDAYO resulted in a mean increase in heart rate of 4 to 5 beats per minute from baseline compared to 0.5 beat per minute with placebo.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20a%20pool%20of%20Trials%201%20and%202%2C%20tachycardia,beat%20per%20minute%20with%20placebo.)

> “Pulse Rate (beats per minute)
> Baseline mean	73.7	73	73	73.5	74.2	75.9	73.7	74.6
> Change from baselineb	0.6	3.6	3.9	4.6	0.4	2.8	3.9	3.6
> Difference from placebo (95% CI)b		3.1
> (2.2, 4)d	3.4
> (2.5, 4.2)d	4.1
> (3.1, 5)d		2.4
> (1.3, 3.6)d	3.5
> (2.4, 4.6)d	3.2
> (2, 4.4)d”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Pulse%20Rate%20%28beats%20per%20minute%29,%282%2C%204.4%29d)

> “At 72 weeks, participants in the Foundayo-treated groups had an increase in the mean pulse rate of 4.3 to 5.3 beats per minute compared with a mean baseline of 73.0 to 73.5 beats/minute. The placebo arm had a mean pulse rate increase of 0.8 beats/minute with a mean baseline of 73.7 beats/minute.<sup>3</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Clinical Data & How It Works, captured 2026-11-14](https://foundayo.lilly.com/hcp/clinical-data#:~:text=At%2072%20weeks%2C%20participants%20in,a%20mean%20baseline%20of%2073.7)

Note: The first passage is from the Prescribing Information (pool of Trials 1 and 2). The second is the pulse rate row of Table 7 of the Prescribing Information; its columns are Trial 1 (without diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, then Trial 2 (with type 2 diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, as in the table header. In each "difference from placebo" row the placebo cells are empty. Footnote d marks results not controlled for multiplicity. The Prescribing Information is the governing source: Table 7 gives Trial 1 (ATTAIN-1) mean pulse rate changes of 3.6, 3.9, and 4.6 beats per minute for Foundayo 5.5 mg, 9 mg, and 17.2 mg against 0.6 with placebo. The third passage, from the cardiometabolic section of the clinical data page of the Foundayo HCP site, gives ATTAIN-1 increases of 4.3 to 5.3 beats per minute against 0.8 with placebo, citing the ATTAIN-1 publication; the two sources differ on these figures. The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-qt-prolongation"></a>

### Does Foundayo prolong the QT interval?

> “At 1.4 times the mean of maximum concentrations provided by the maximum recommended FOUNDAYO dose (17.2 mg) once daily, clinically significant QTc interval prolongation was not observed.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=At%201.4%20times%20the%20mean,interval%20prolongation%20was%20not%20observed.)

<a id="foundayo-hypotension"></a>

### Can Foundayo cause low blood pressure?

> “In a pool of Trials 1 and 2, hypotension occurred more frequently among patients taking FOUNDAYO (2%) than patients taking placebo (0.5%). Hypotension was more frequently seen in FOUNDAYO-treated patients on concomitant antihypertensive therapy (4%) compared to FOUNDAYO-treated patients not on antihypertensive therapy (1%).”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20a%20pool%20of%20Trials%201%20and%202%2C%20hypotension,not%20on%20antihypertensive%20therapy%20%281%25%29.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-hair-loss"></a>

### Does Foundayo cause hair loss?

> “Hair loss adverse reactions in FOUNDAYO-treated patients were associated with weight reduction. In a pool of Trials 1 and 2, hair loss was reported more frequently in female than male patients in the FOUNDAYO (7% female versus 0.9% male) and placebo (3% female versus 0.7% male) treatment groups.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Hair%20loss%20adverse%20reactions%20in,versus%200.7%25%20male%29%20treatment%20groups.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-dizziness"></a>

### Does Foundayo cause dizziness?

> “In a pool of Trials 1 and 2, dizziness was reported in 4% of FOUNDAYO-treated patients and 3% of placebo-treated patients.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20a%20pool%20of%20Trials%201%20and%202%2C%20dizziness,and%203%25%20of%20placebo%2Dtreated%20patients.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-dysgeusia"></a>

### Does Foundayo cause taste changes (dysgeusia)?

> “In a pool of Trials 1 and 2, dysgeusia was reported in 0.9% of FOUNDAYO-treated patients and 0.3% of placebo-treated patients.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20a%20pool%20of%20Trials%201%20and%202%2C%20dysgeusia,and%200.3%25%20of%20placebo%2Dtreated%20patients.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-dysesthesia"></a>

### Does Foundayo cause dysesthesia?

> “In a pool of Trials 1 and 2, dysesthesia was reported in 0.3% and 1% of patients treated with FOUNDAYO 9 mg, and 17.2 mg, respectively, and 0.1% of patients receiving placebo. No patients taking FOUNDAYO 5.5 mg reported dysesthesia.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20a%20pool%20of%20Trials%201%20and%202%2C%20dysesthesia,FOUNDAYO%205.5%20mg%20reported%20dysesthesia.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-glp1-postmarketing"></a>

### Which GLP-1 receptor agonist postmarketing reactions does the Foundayo label list?

> “The following adverse reactions have been reported during post-approval use of GLP-1 receptor agonists. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
>
> Gastrointestinal Disorders: acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death; ileus, intestinal obstruction, severe constipation including fecal impaction
>
> Hypersensitivity: anaphylaxis, angioedema
>
> Pulmonary: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation
>
> Renal and Urinary Disorders: acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=The%20following%20adverse%20reactions%20have,renal%20failure%2C%20sometimes%20requiring%20hemodialysis)

Note: These reactions were reported for GLP-1 receptor agonists as a class.

## Warnings

<a id="foundayo-severe-gi"></a>

### Can Foundayo cause severe stomach problems?

> “Use of FOUNDAYO has been associated with gastrointestinal adverse reactions, sometimes severe. In clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients treated with orforglipron (approximately 3%) than patients who received placebo (1%). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists [see Adverse Reactions (6)]. FOUNDAYO is not recommended in patients with severe gastroparesis.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Use%20of%20FOUNDAYO%20has%20been,in%20patients%20with%20severe%20gastroparesis.)

<a id="foundayo-gastroparesis"></a>

### Can people with gastroparesis take Foundayo?

> “FOUNDAYO is not recommended in patients with severe gastroparesis.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Adverse%20Reactions%20%286%29%5D.-,FOUNDAYO%20is%20not%20recommended%20in%20patients%20with%20severe%20gastroparesis.)

<a id="foundayo-boxed-warning-thyroid"></a>

### Does Foundayo cause thyroid cancer (boxed warning)?

> “WARNING: RISK OF THYROID C-CELL TUMORS
> In products with glucagon-like peptide-1 (GLP-1) receptor agonist activity that are pharmacologically active in rats and mice, rodent thyroid C-cell tumors (adenomas and carcinomas) have been observed at clinically relevant exposures and are considered GLP-1 receptor-dependent effects in rodents. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents [see Nonclinical Toxicology (13.1)]. While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].
> FOUNDAYO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of FOUNDAYO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with FOUNDAYO [see Contraindications (4), Warnings and Precautions (5.1)].”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=WARNING%3A%20RISK%20OF%20THYROID%20C%2DCELL,%284%29%2C%20Warnings%20and%20Precautions%20%285.1%29%5D.)

> “Orforglipron is not pharmacologically active in rats or mice. In a 2-year rat carcinogenicity study, orforglipron was non-carcinogenic at oral daily doses of 5, 30, and 200 mg/kg/day resulting in exposures approximately 3, 9, and 26 times the clinical exposure at the MRHD, respectively, based on AUC. In a 26-week study in Tg.RasH2 transgenic mice, orforglipron was non-carcinogenic at oral daily doses of 5, 30, and 200 mg/kg/day. For other GLP-1 receptor agonists that are pharmacologically active in rats, thyroid C-cell hyperplasia, and thyroid C-cell adenoma and carcinoma have been observed at clinically relevant exposures and are considered an on-target class effect. Orforglipron would be expected to have the same on-target class effect if it was pharmacologically active in rats. The human relevance of these findings is unknown.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Orforglipron%20is%20not%20pharmacologically%20active%20in%20rats%20or%20mice.,of%20these%20findings%20is%20unknown.)

<a id="foundayo-contraindications"></a>

### Who should not take Foundayo (contraindications)?

> “FOUNDAYO is contraindicated in patients with:
>
> A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].
> Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists [see Warnings and Precautions (5.6), Adverse Reactions (6.2)].”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%20is%20contraindicated%20in%20patients%20with%3A,Precautions%20%285.6%29%2C%20Adverse%20Reactions%20%286.2%29%5D.)

<a id="foundayo-pancreatitis"></a>

### Can Foundayo cause pancreatitis?

> “Acute pancreatitis has been reported in patients treated with FOUNDAYO. Fatal and non-fatal hemorrhagic or necrotizing pancreatitis have been observed in patients treated with GLP-1 receptor agonists [see Adverse Reactions (6)]. After initiation of FOUNDAYO, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back) and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue FOUNDAYO and initiate appropriate management.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Acute%20pancreatitis%20has%20been%20reported,FOUNDAYO%20and%20initiate%20appropriate%20management.)

> “In a pool of Trials 1 and 2, 6 events of acute pancreatitis were confirmed by adjudication in 6 FOUNDAYO-treated patients (0.14 patients per 100 years of exposure) versus 2 events in 1 placebo-treated patient (0.04 patients per 100 years of exposure).”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20a%20pool%20of%20Trials%201%20and%202%2C%206,per%20100%20years%20of%20exposure%29.)

> “In a pool of Trials 1 and 2, treatment with FOUNDAYO resulted in mean increases from baseline in serum pancreatic amylase concentrations of 16% to 20% and serum lipase concentrations of 26% to 31%, compared to mean increases from baseline in serum pancreatic amylase of 3% and serum lipase of 4% in placebo-treated patients. The clinical significance of elevations in amylase or lipase with FOUNDAYO is unknown in the absence of other signs and symptoms of pancreatitis.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20a%20pool%20of%20Trials%201%20and%202%2C%20treatment,signs%20and%20symptoms%20of%20pancreatitis.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-gallbladder"></a>

### Can Foundayo cause gallbladder problems or gallstones?

> “Treatment with FOUNDAYO and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease. In a pool of two clinical trials for weight reduction (Trials 1 and 2), cholelithiasis was reported in 1% of patients treated with orforglipron once daily and 0.7% of placebo-treated patients, and acute cholecystitis was reported in 0.4% of patients treated with orforglipron once daily and 0.3% of placebo-treated patients [see Adverse Reactions (6)]. Acute gallbladder events were associated with weight reduction. If cholecystitis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Treatment%20with%20FOUNDAYO%20and%20GLP%2D1,appropriate%20clinical%20follow%2Dup%20are%20indicated.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-kidney"></a>

### Can Foundayo cause kidney problems?

> “There have been reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists or FOUNDAYO. The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6)]. Monitor renal function in patients reporting adverse reactions to FOUNDAYO that could lead to volume depletion, especially during dosage initiation and escalation of FOUNDAYO.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=There%20have%20been%20reports%20of,initiation%20and%20escalation%20of%20FOUNDAYO.)

> “In a pool of Trials 1 and 2, acute kidney injury was reported in 0.2% of FOUNDAYO-treated patients compared to 0.05% of placebo-treated patients.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20a%20pool%20of%20Trials%201%20and%202%2C%20acute,to%200.05%25%20of%20placebo%2Dtreated%20patients.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-hypoglycemia"></a>

### Does Foundayo cause low blood sugar?

> “FOUNDAYO lowers blood glucose and can cause hypoglycemia.
>
> In a trial of adults with type 2 diabetes and BMI ≥27 kg/m2 (Trial 2), hypoglycemia (plasma glucose <54 mg/dL) was reported in 2% of patients treated with orforglipron versus 0.2% of patients receiving placebo. One patient treated with orforglipron and no patients receiving placebo reported severe hypoglycemia in Trial 2. In Trial 2, 7% of patients treated with orforglipron once daily in combination with sulfonylurea reported hypoglycemia compared with 0.5% of patients not taking a sulfonylurea [see Adverse Reactions (6.1)]. There is also increased risk of hypoglycemia in patients treated with FOUNDAYO in combination with insulin [see Drug Interactions (7.2)]. Hypoglycemia has also been associated with FOUNDAYO and GLP-1 receptor agonists in adults without type 2 diabetes [see Adverse Reactions (6.1)].
>
> Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. In patients with diabetes, monitor blood glucose prior to starting FOUNDAYO and during FOUNDAYO treatment. The risk of hypoglycemia may be lowered by a reduction in the dose of insulin or sulfonylurea (or other concomitantly administered insulin secretagogue).”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%20lowers%20blood%20glucose%20and,other%20concomitantly%20administered%20insulin%20secretagogue%29.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-hypersensitivity"></a>

### Can Foundayo cause allergic reactions?

> “Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists [see Adverse Reactions (6.2)]. If hypersensitivity reactions occur, advise the patient to promptly seek medical attention and discontinue use of FOUNDAYO. FOUNDAYO is contraindicated in patients with a prior serious hypersensitivity reaction to orforglipron or to any of the excipients in FOUNDAYO. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with FOUNDAYO.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=5.6%20Hypersensitivity%20Reactions-,Serious%20hypersensitivity%20reactions%20%28e.g.%2C%20anaphylaxis%2C%20angioedema%29%20have%20been%20reported%20with,to%20these%20reactions%20with%20FOUNDAYO.)

> “In a pool of Trials 1 and 2, hypersensitivity reactions, including anaphylactic reaction, occurred in 0.5% of FOUNDAYO-treated patients compared to 0.3% of placebo-treated patients.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=In%20a%20pool%20of%20Trials%201%20and%202%2C%20hypersensitivity,to%200.3%25%20of%20placebo%2Dtreated%20patients.)

Note: The Prescribing Information presents these safety data from trials of an investigational orforglipron formulation, shown as equivalent dosages of once-daily Foundayo.

<a id="foundayo-diabetic-retinopathy"></a>

### Can Foundayo worsen diabetic retinopathy?

> “Temporary worsening of diabetic retinopathy has been reported with rapid improvement in glucose control. FOUNDAYO has not been studied in patients with diabetic retinopathy and/or macular edema requiring acute treatment. Monitor patients with a history of diabetic retinopathy for progression of diabetic retinopathy.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Temporary%20worsening%20of%20diabetic%20retinopathy,for%20progression%20of%20diabetic%20retinopathy.)

<a id="foundayo-surgery-anesthesia"></a>

### Should Foundayo be stopped before surgery or anesthesia?

> “FOUNDAYO delays gastric emptying [see Clinical Pharmacology (12.2)]. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
>
> Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking FOUNDAYO, including whether modifying preoperative fasting recommendations or temporarily discontinuing FOUNDAYO could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking FOUNDAYO.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%20delays%20gastric%20emptying%20%5Bsee,if%20they%20are%20taking%20FOUNDAYO.)

## Related pages
- [Medical information: Foundayo (orforglipron): Chronic weight management](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/access-and-coverage)
